PCM
CLVS

Peregrine Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Peregrine Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-143,613
Closed -$11.8M – 254
2017
Q3 		$11.8M Buy
143,613
+17,443
+14% +$1.38M 0.28% 142
2017
Q2 		$11.8M Buy
+126,170
New +$7.72M 0.29% 142

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Peregrine Capital Management's CLVS Position: Q4 2017 in Review

Peregrine Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2017, closing a stake of 143,613 shares — an estimated $11.8M sold.

Peregrine Capital Management first reported a position in CLVS in Q2 2017 and held it in 2 quarters. The position peaked at $11.8M in Q3 2017. 247 funds tracked by Wall St. Rank hold CLVS as of Q4 2017.

  • Peregrine Capital Management reported no remaining Clovis Oncology, Inc. position as of Q4 2017 after selling out during the quarter.
  • Peregrine Capital Management sold 143,613 Clovis Oncology, Inc. shares in Q4 2017, an estimated $11.8M.
  • Peregrine Capital Management first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 2 quarters.
  • Peregrine Capital Management's Clovis Oncology, Inc. position peaked at $11.8M in Q3 2017.
  • 247 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2017.

Based on Peregrine Capital Management's 13F filing for Q4 2017, filed 24 Jan 2018.